National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ibrutinib (Imbruvica®) HTA ID:20032

Ibrutinib (Imbruvica®) is indicated as a single agent or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

NCPE Assessment Process Complete
Rapid Review Commissioned 06/07/2020
Rapid Review Completed 04/08/2020
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Ibrutinib as a single agent or in combination with obinutuzumab for adult patients with previously untreated CLL compared with the current standard of care.